BIOL: BIOLASE, Inc. (NASDAQ: BIOL)

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, newly declared select unaudited preliminary fiscal results for the 3rd-quarter finished September 30, 2k19.

Select Preliminary 3rd-Quarter 2k19 Unaudited Financial Results:

  • Revenue is expected to be in the range of $8.50M to $8.80M.
  • Loss from operations is expected to be in the range of ($4.80)M to ($5.20)M as the Company raised its allowance for doubtful accounts by about $1.10M to fully reserve for payments still owed to it by its Chinese distributor.
  • Net loss is expected to be in the range of ($5.40)M to ($5.80)M.
  • 3rd-quarter adjusted EBITDA is anticipated to be in the range of ($2.70)M to ($3.10)M. The Company continues to expect to be adjusted EBITDA break-even in the 4th-quarter of 2k19, which is historically the Company’s strongest quarter.